// Workers AI · dad joke modeIs Nizatidine a heartburn med? It's a tablet to aid digestion, right?
 | |
| Clinical data | |
|---|---|
| Trade names | Axid, Tazac |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >70% |
| Protein binding | 35% |
| Metabolism | Liver |
| Elimination half-life | 1–2 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.155.683 |
| Chemical and physical data | |
| Formula | C12H21N5O2S2 |
| Molar mass | 331.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.[2]
It was patented in 1980 and approved for medical use in 1988.[3][4] It was developed by Eli Lilly.
Medical use
[edit]Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[5]
Adverse effects
[edit]Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[5]
History and development
[edit]Nizatidine was developed by Eli Lilly, and was first marketed in 1988.[3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[6] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[7] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[8] protecting the product) to Braintree Laboratories.[9]
Society and culture
[edit]Brand names
[edit]Brand names include Tazac[citation needed] and Axid.[10]
References
[edit]- ↑ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
- ↑ Romero M, Franzosi MG (1989). "[Nizatidine]". Medicina (in Italian). 9 (1). Florence, Italy: 93–96. PMID 2567957.
- 1 2 "Nizatidine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 20 March 2020.
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN 978-3-527-60749-5.
- 1 2 "Nizatidine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 25 January 2018. PMID 31643707. NBK548387. Retrieved 19 March 2020.
- ↑ "Eli Lilly and Company and Reliant Pharmaceuticals Announce Agreement for U.S. Sales and Marketing Rights to Axid(R)". Encyclopedia.com. 7 September 2000. Archived from the original on May 26, 2008.
- ↑ "Reliant Pharmaceuticals to Launch AxidŽ Oral Solution". Reliant Pharmaceuticals, LLC. 26 July 2004.
- ↑ US 6930119, Bobotas G, Fawzy AA, "Liquid pharmaceutical composition", published 2005-08-16, issued 24 June 2005, assigned to Reliant Pharmaceuticals, LLC and Braintree Laboratories Inc
- ↑ "Reliant Pharmaceuticals Announces the Sale of Axid® Oral Solution to Braintree Laboratories". Reliant Pharmaceuticals, LLC. Archived from the original on August 14, 2007.
- ↑ Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, Weston IE, Kearns GL (February 2003). "The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule". Journal of Clinical Pharmacology. 43 (2): 148–153. doi:10.1177/0091270002239823. PMID 12616667.
